Background/Aims: Massive proteinuria, a significant sign of nephrotic syndrome (NS), has the potential to injure tubular epithelial cells (TECs). Furosemide is widely used for the treatment of edema, a common manifestation of NS. However, whether furosemide treatment affects massive proteinuria-induced TEC injury in patients with NS is unknown. Methods: The effect of furosemide on TEC damage was investigated in vitro. In addition, a clinical study was conducted to study whether the short-term treatment of nephrotic edema with furosemide could exacerbate TEC injury. Results: The proliferation of in vitro human kidney-2 (HK-2) cells exposed to massive urinary protein (8 mg/mL) significantly decreased (P<0.05), while the levels of kidney injury molecule-1 (Kim-1) and neutrophil gelatinase associated lipocalin (NGAL) in the supernatants significantly increased (P<0.05). Importantly, furosemide treatment did not further increase the expression of Kim-1 and NGAL in HK-2 cells upregulated by massive proteinuria. For the clinical study, 26 patients with NS, all prescribed the recommended dosage of prednisone (1 mg/kg/day), were randomly assigned to two groups. One group (n=13) received furosemide (60-120 mg/day, intravenously) for 1 week; the remaining participants (control group) did not receive furosemide or any other diuretics. The results showed that the 24-h urine volume in the furosemide-treated group was slightly, but not significantly, higher than that in the control group (P>0.05). In addition, serum levels of BUN, Scr, Cys C, and urinary Kim-1 and NGAL were not significantly different between the two groups (all P>0.05). Twenty-three patients underwent a renal biopsy. Of these, 22 patients exhibited vacuolar degeneration of the TECs; 8 patients showed brush border membrane shedding of the TECs; and 12 patients showed protein casts. However, there were no significant differences between the two groups (all P>0.05). Conclusion: In summary, massive proteinuria induced the injury of TECs in patients with NS, and furosemide treatment did not aggravate this injury.
Introduction
Severe edema is one of the main manifestations of nephrotic syndrome (NS). Furosemide, a type of loop diuretic, has been widely used for the management of edema in patients with NS [1] . However, a series of studies suggested that furosemide may be a potential nephrotoxic drug. Furosemide, when combined with gentamicin [2], cephalosporin [3, 4] , or vancomycin [5] , augmented nephrotoxicity. Furthermore, it has been shown that forced diuresis with furosemide is associated with a higher risk of contrast-induced nephropathy [6] . Recent reports also indicate that furosemide is associated with acute kidney injury (AKI). When used in adult patients in an intensive care unit (ICU) setting [7, 8] , or in patients in pediatric ICU [9] , furosemide increased the risk of AKI. These studies together suggest that furosemide may be a potential nephrotoxic drug that when combined with other renal injury factors, increases the risk of kidney injury.
Severe proteinuria is another important clinical manifestation in patients with NS. We have previously demonstrated urinary protein-induced epithelial-mesenchymal transdifferentiation (EMT) and cellular apoptosis of tubular epithelial cells (TECs) [10, 11] . In addition, other studies using a single component (such as plasma proteins and bovine Serum Albumin (BSA)), have also confirmed that urinary proteins accelerate kidney disease progression via inflammatory induction, apoptotic responses, or fibrogenesis in the renal tubulointerstitium [12] [13] [14] [15] . However, whether furosemide increases renal toxicity in response to the addition of urinary protein remains unknown.
It is known that AKI is more likely to occur in patients with NS [16] . Hence, we are interested in understanding whether furosemide treatment exacerbates the injury of TECs induced by massive proteinuria in NS. This study was designed to test this hypothesis in vitro and in vivo.
Materials and Methods

In vitro Studies
Extraction of urinary proteins. Urinary proteins were extracted from the urine of patients with untreated and biopsy-proven idiopathic NS using an ammonium sulfate precipitation and dialysis method, as described previously [17] .
Cell culture and treatments. Human proximal tubular HK-2 cells (ATCC, Manassas, VA, USA) were incubated in Dulbecco's modified Eagle's medium (DMEM, Gibco, Grand Island, NY, USA), supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY, USA), under standard conditions. The cells were exposed to urinary protein, furosemide, or furosemide plus urinary protein before analysis.
Determination of biomarkers for TEC injury by ELISA. The levels of neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule (Kim)-1 in patients' urine and in cell culture supernatants were measured with commercially available enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN, USA), according to manufacturer instructions.
Cell viability assay. Cells were incubated with 5 mg/mL methyl thiazolyl tetrazolium (MTT) solution (Calbiochem, San Diego, CA, USA) for 4 h at 37°C. The formazan crystals were dissolved in dimethyl sulfoxide. Optical density was determined at 492 nm with a plate reader (M550, Bio-Rad, Hercules, CA, USA).
Determination of biomarkers for renal function by automatic biochemical analyzer. The levels of serum creatinine (Scr), blood urea nitrogen (BUN), and cystatin C (Cys C) were measured using an automatic biochemical analyzer (Cobas 8000, Roche, Basel, Switzerland).
Patients
Inclusion criteria: Patients who conformed with the diagnostic criteria for NS (nephrotic-range proteinuria >3.5 g/24 h and serum albumin <30 g/L) with moderate edema, aged from 14 to 70 years, and who had signed their informed consent.
Exclusion criteria: Patients with hypokalemia (serum potassium <3.5 mmol/L), pregnancy, a history of any diuretic drug use within 2 weeks, previous kidney transplantation, malignancy, creatinine clearance Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry <60 mL/min, serious infection, thromboembolism, other causes of edema including heart failure, and liver cirrhosis. Study design: The study was a prospective randomized single-blind controlled trial. All the included patients were prescribed the recommended dosage of prednisone (1 mg/kg/day) and randomly assigned to either the furosemide group or the control group, according to a table of random numbers. The furosemide group received furosemide (60-120 mg/day, Guangdong Nanguo Pharmaceutical Co, Ltd, Guangdong, China) by intravenous infusion for 1 week; the control group received no diuretic therapy. All patients were followed for 7 days, and daily urine volume, renal function, and any biomarkers of TEC injury in the patients' urine were observed dynamically.
Statistical analysis
All statistical tests were performed with SPSS 19.0. Data were expressed as means ± standard error of the mean (S.E.M.). Two group comparisons were carried out using matched t tests, followed by a Wilcoxon rank test. Multiple group comparisons were performed using analysis of variance (ANOVA), followed by Bonferroni or Tamhane's T2 tests. For repeated measures, data were analyzed using a repeated measure ANOVA. The P value was considered statistically significant if less than 0.05.
Results
The effect of furosemide on TEC damage
We first explored whether furosemide could exacerbate renal TEC injury, induced by urinary protein, in vitro. The viability of cultured HK-2 cells of the TEC line, treated with furosemide (0.5 mM or 1.0 mM) and tested using the MTT method, remained unaffected at 16 h, 24 h, and 36 h ( Fig. 1-A , B, and C). We then employed a protein overload model of cultured HK-2 cells to explore whether furosemide, in addition to urinary protein, would affect cell viability. To mimic the pathological process of proteinuria-induced TEC injury in patients with NS, we used urinary protein extracted from NS patients. Cell viability was significantly inhibited in response to 8 mg/mL urinary protein treatment at 16 h (P<0.05), but there was no additional effect on cell viability following furosemide exposure (0.5 mM or 1.0 mM) ( Fig. 1-D) .
The expression levels of tubule injury biomarkers (Kim-1 and NGAL) in HK-2 cells treated with furosemide (0.5 mM or 1.0 mM), as measured by ELISA assays at 16 h, were not increased. Further, when cultured HK-2 cells were treated with 8 mg/mL urinary protein or urinary protein (8 mg/ mL) with furosemide (0.5 mM or 1.0 mM) for 16 h, the levels of Kim-1 and NGAL were significantly increased compared to the control group (P<0.05). Kim-1 and NGAL levels did increase in the urinary protein plus furosemide treated group, however they were not significantly higher than Fig. 1-E, F) .
The demographic and baseline characteristics of patients
All 26 patients completed the study. There were no differences in the demographic or baseline characteristics of included patients between groups ( Table 1) .
The effect of furosemide on urine volume in patients with NS
To assess the diuretic effects of furosemide, 24-h urine volumes of all patients were recorded. As shown in Fig.  2 , the 24-h urine volume increased in both groups over the course of the 1-week treatment and was significantly higher after 2 days of treatment, compared to the baseline levels on day 0 (P<0.05). However, the urine volumes in the furosemide-treated group were not significantly different from those in the control group (P=0.357).
The effect of furosemide on kidney injury in patients with NS
To study whether the loop diuretic, furosemide, augments renal damage in patients with NS, we first examined all patients for the biomarkers for renal function, including serum levels of BUN, Scr, and Cys C, during the experimental period. As shown in Fig. 3-A, B , and C, the serum levels of BUN, Scr, and Cys C in the furosemide- 
(D and E)
Changes in the levels of Kim-1 and NGAL in the urine of patients after treatment for 0, 3, and 7 days. The data are expressed as means ± S.E.M., and the two-group comparison is calculated using a repeated measurement data ANOVA. Changes in 24-h urine volume of patients after treatment for 0, 1, 2, 3, 4, 5, 6 and 7 days. The data are expressed as means ± S.E.M., and the two-group comparison is calculated using a repeated measurement data ANOVA, *P<0.05, compared with 0 days. treated group were not significantly different to those in the control group (P>0.05). Likewise, the concentrations of biomarkers of TEC injury, Kim-1 and NGAL (normalized to urinary creatinine levels), in the furosemide-treated group were not significantly different from those in the control group (Fig. 3-D and E; all P>0.05 ).
Histomorphological comparison of tubule pathology
In the current study, 13 patients in the control group and 10 patients in the furosemide-treated group were subjected to renal biopsies, in order to assess pathology after 1 week of each treatment. As shown in Table 2 , minimal change nephrotic syndrome (MCNS) was the most common type of pathology observed. Tubular injury, as defined by vacuolar degeneration, brush border membrane shedding, or protein cast formation was present in all 23 patients who underwent renal biopsy; of these, 22 patients exhibited vacuolar degeneration of the TECs (Fig. 4) , 8 patients showed brush border membrane shedding of the TECs, and in 12 patients protein casts were observed. There was no difference in the incidence of vacuolar degeneration between the furosemidetreated and control groups (100% vs. 92.3%, P=1.000). In addition, we found no significant differences in the incidence of protein cast formation (50% vs. 53.8%, P=1.000) or brush border membrane shedding (50% vs. 23.7%, P=0.367) between the two groups.
Discussion
To examine the effect of protein overload on TECs, most previous studies used a single protein component, such as plasma albumin or BSA [12] [13] [14] [15] . In a clinical setting, the glomerular ultrafiltrate contains a mixture of proteins including albumin, transferrin, and IgG. In addition, protein frequently undergoes modifications, such as phosphorylation, glycosylation, methylation, and hydroxylation under pathological conditions [18] . This study aimed to mimic, as closely as possible, the conditions encountered in protein overload proteinuria in vivo. To this end, urinary protein extracted from the urine of patients with NS was used in this study. It is well-known that kidneys have a great capacity for regeneration and recovery after tubular damage; TEC proliferation potentially leads to the replacement of necrotic TECs and the reconstruction of the cytoskeleton and thus, gradually restores the kidney after injury [19] . Hence, impaired TEC proliferation can promote the development of kidney injury. Here, we showed that, when exposed to massive concentrations of urinary proteins, TEC proliferation was significantly inhibited. Furosemide treatment had no effect on the proliferation of TECs; moreover, it did not inhibit TEC proliferation following exposure to massive concentrations of urinary proteins.
Kim-1 is upregulated in proximal TECs in kidneys after ischemic or toxic injury [20] ; NGAL is expressed by TECs in response to injury and tubulointerstitial damage [21] . Urinary Kim-1 and NGAL are good predictors of tubule injury [21, 22] . Here, we found that when TECs were exposed to urinary protein, the levels of Kim-1 and NGAL in the supernatants significantly increased. Furosemide treatment alone did not increase the expression levels of these tubule injury biomarkers; nor did it further augment their levels of expression upregulated by massive proteinuria. In conclusion, these results indicate that although proteinuria is a key inducer of TEC injury in patients with NS, furosemide had no direct cytotoxic effect on TECs and does not further aggravate the cytotoxic effects of proteinuria overload. Further, we conducted a clinical study to investigate whether short-term treatment of nephrotic edema with the recommended dosage of furosemide (<120 mg/day) could injure TECs. Our results showed that vacuolar degeneration, brush border membrane shedding, and protein casts were widely observed in the renal pathology of NS patients with massive proteinuria. These results, together with the ones obtained from the in vitro studies, therefore suggest that massive proteinuria induces the injury of TECs in patients with NS. Intriguingly, aggravated tubule injury following furosemide treatment was not observed. In addition, the levels of renal function parameters (serum levels of BUN, Scr, and Cys C) and urine tubule injury biomarkers (Kim-1 and NGAL) did not increase during furosemide treatment. Thus, these data suggest that massive proteinuria can induce TEC injury in patients with NS, and that short-term treatment of nephrotic edema with the recommended dosage of furosemide did not aggravate this injury.
The mechanism whereby furosemide effectively reduces edema is related to increased diuresis [1] . In our study, 24-h urine volume increased after furosemide treatment for 1 week; however, the increased 24-h urine volumes were not significantly different from those of the control group. Hypoalbuminemia may potentially contribute to diuretic resistance and lead to a reduction in diuretic effect [23] [24] [25] . Consistent with this, we found that the 24-h urine volume increased in the control group of patients along with the treatment group. Meanwhile, oral prednisone is the mainstay treatment for adult MCNS [26] . Prednisone therapy can lead to a complete remission in over 80% of adults MCNS (increased urine volume is one of the criteria for evaluating the remission) [26] . Since MCNS is the most common type of pathology observed in the present study, it is possible that the efficacy of corticosteroids may be the cause of the 24-h urine volume increase in both the control group of patients and the treatment group simultaneously.
In conclusion, our study indicates that massive proteinuria can induce the injury of TECs in patients with NS, while furosemide treatment does not aggravate this injury, furosemide may insufficiently to increase urine output in hypoalbuminemic patients.
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